AtaiBeckley Shares Tick Higher After Mid-Stage R-MDMA Trial Shows Positive Results
AtaiBeckley shares rose 2% in premarket trading after the company reported positive mid-stage results for EMP-01, its experimental R-MDMA oral formulation intended to treat severe fear of social situations. In a trial of 71 adults the treated group outperformed placebo on a standard symptom scale and a higher proportion of treated patients were rat…